Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2015-2017

ABSTRACT

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS. Detailed Description Chronic rhinosinusitis (CRS) impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The prevalence of Chronic Rhinosinusitis with Nasal Polyps(CRSwNP) in Europe has been estimated to be 2-4.3% and is thought to be similar in the United States. Corticosteroids remain the mainstay of treatment although novel therapies are being developed based on an evolving understanding of the inflammatory pathways involved in disease pathogenesis. CRSwNP is characterized by the presence of edematous polypoid mucosa and predominantly eosinophilic inflammation. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). P-gp is a 170 kiloDalton membrane protein which belongs to sub-family B of the adenosine triphosphate(ATP)-binding cassette(ABC) transporter superfamily. P-gp utilizes ATP hydrolysis to transport a wide range of substrates across the plasma membrane. P-gp mediated transport has been observed in the regulation of cytokine secretion in both human T-cells as well as sinonasal epithelial cells implicating a potential immunomodulatory role. Studies by our group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. Verapamil Hydrochloride(HCl) was one of the first inhibitors of P-gp to be identified in 1982 and also functions as a calcium channel blocker(CCB). Verapamil has since been categorized as a first generation P-gp inhibitor as more potent and selective 2nd and 3rd generation molecules were subsequently developed for use as chemotherapy sensitizers. Several studies, including those by our group, have reported that Verapamil is capable of modulating inflammatory responses in human T-cells, animal models of asthma, and nasal polyps. Using an organotypic explant model, we have previously shown that Verapamil has similar effects to dexamethasone in its ability to abrogate Interleukin(IL)-5, IL-6, and Thymic Stromal Lymphopoietin secretion. While Verapamil is cardioactive, it is considered the first-line prophylactic drug for cluster headache and is usually well tolerated by otherwise healthy patients. In light of our prior studies demonstrating the immunomodulatory role of P-gp in promoting Th2 skewing cytokine secretion in CRSwNP, we hypothesized that low dose Verapamil HCl monotherapy would be safe and effective in the treatment of CRSwNP. More... »

URL

https://clinicaltrials.gov/show/NCT02454608

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2581", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.\n\nDetailed Description\nChronic rhinosinusitis (CRS) impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The prevalence of Chronic Rhinosinusitis with Nasal Polyps(CRSwNP) in Europe has been estimated to be 2-4.3% and is thought to be similar in the United States. Corticosteroids remain the mainstay of treatment although novel therapies are being developed based on an evolving understanding of the inflammatory pathways involved in disease pathogenesis. CRSwNP is characterized by the presence of edematous polypoid mucosa and predominantly eosinophilic inflammation. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). P-gp is a 170 kiloDalton membrane protein which belongs to sub-family B of the adenosine triphosphate(ATP)-binding cassette(ABC) transporter superfamily. P-gp utilizes ATP hydrolysis to transport a wide range of substrates across the plasma membrane. P-gp mediated transport has been observed in the regulation of cytokine secretion in both human T-cells as well as sinonasal epithelial cells implicating a potential immunomodulatory role. Studies by our group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. Verapamil Hydrochloride(HCl) was one of the first inhibitors of P-gp to be identified in 1982 and also functions as a calcium channel blocker(CCB). Verapamil has since been categorized as a first generation P-gp inhibitor as more potent and selective 2nd and 3rd generation molecules were subsequently developed for use as chemotherapy sensitizers. Several studies, including those by our group, have reported that Verapamil is capable of modulating inflammatory responses in human T-cells, animal models of asthma, and nasal polyps. Using an organotypic explant model, we have previously shown that Verapamil has similar effects to dexamethasone in its ability to abrogate Interleukin(IL)-5, IL-6, and Thymic Stromal Lymphopoietin secretion. While Verapamil is cardioactive, it is considered the first-line prophylactic drug for cluster headache and is usually well tolerated by otherwise healthy patients. In light of our prior studies demonstrating the immunomodulatory role of P-gp in promoting Th2 skewing cytokine secretion in CRSwNP, we hypothesized that low dose Verapamil HCl monotherapy would be safe and effective in the treatment of CRSwNP.", 
    "endDate": "2017-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02454608", 
    "keywords": [
      "double blind placebo", 
      "verapamil", 
      "chronic rhinosinusitis", 
      "calcium channel blocker", 
      "inflammation", 
      "tissue", 
      "eosinophilic inflammation", 
      "animal model", 
      "asthma", 
      "P-Glycoprotein", 
      "inhibitor", 
      "Cr", 
      "overexpression", 
      "american", 
      "healthcare expenditure", 
      "prevalence", 
      "nasal polyp", 
      "CRSwNP", 
      "Europe", 
      "United State", 
      "corticosteroid", 
      "mainstay", 
      "novel therapy", 
      "evolving understanding", 
      "inflammatory pathway", 
      "disease pathogenesis", 
      "Recent evidence", 
      "epithelial cell", 
      "primary driver", 
      "dysregulated immune response", 
      "Bodily Secretion", 
      "helper T cell", 
      "Th2", 
      "cytokine", 
      "local immune response", 
      "cytokine secretion", 
      "efflux", 
      "Adenosine Triphosphate", 
      "ATP-binding cassette", 
      "cassette", 
      "transporter", 
      "ATP hydrolysis", 
      "transport", 
      "wide range", 
      "substrate", 
      "Cell Membrane", 
      "Formal Social Control", 
      "human T cell", 
      "immunomodulatory role", 
      "Mucous Membrane", 
      "patient", 
      "polarizing", 
      "target", 
      "HCl", 
      "first generation", 
      "generation", 
      "sensitizer", 
      "inflammatory response", 
      "explants", 
      "similar effect", 
      "dexamethasone", 
      "IL", 
      "Interleukin-6", 
      "first line", 
      "headache", 
      "healthy patient", 
      "prior study", 
      "low dose", 
      "monotherapy"
    ], 
    "name": "Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02454608"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00019.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.39479.30", 
        "type": "Organization"
      }
    ], 
    "startDate": "2015-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1111/head.12145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002529252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/alr.21072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003754472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1253/circj.cj-09-0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008378333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moo.0b013e32835bc3f9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009617454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neuropharm.2012.05.033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012770675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00011-005-0060-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019965301", 
          "https://doi.org/10.1007/s00011-005-0060-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pupt.2011.11.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039786003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(89)91076-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041369857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10194-010-0289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042829743", 
          "https://doi.org/10.1007/s10194-010-0289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-4486.2009.01995.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046850455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/01.wnl.0000267319.18123.d3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064349412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078588337", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02454608"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02454608'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02454608'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02454608'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02454608'


 

This table displays all metadata directly associated to this object as RDF triples.

128 TRIPLES      16 PREDICATES      97 URIs      78 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02454608 schema:about anzsrc-for:2581
2 anzsrc-for:3103
3 schema:description Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS. Detailed Description Chronic rhinosinusitis (CRS) impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The prevalence of Chronic Rhinosinusitis with Nasal Polyps(CRSwNP) in Europe has been estimated to be 2-4.3% and is thought to be similar in the United States. Corticosteroids remain the mainstay of treatment although novel therapies are being developed based on an evolving understanding of the inflammatory pathways involved in disease pathogenesis. CRSwNP is characterized by the presence of edematous polypoid mucosa and predominantly eosinophilic inflammation. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). P-gp is a 170 kiloDalton membrane protein which belongs to sub-family B of the adenosine triphosphate(ATP)-binding cassette(ABC) transporter superfamily. P-gp utilizes ATP hydrolysis to transport a wide range of substrates across the plasma membrane. P-gp mediated transport has been observed in the regulation of cytokine secretion in both human T-cells as well as sinonasal epithelial cells implicating a potential immunomodulatory role. Studies by our group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. Verapamil Hydrochloride(HCl) was one of the first inhibitors of P-gp to be identified in 1982 and also functions as a calcium channel blocker(CCB). Verapamil has since been categorized as a first generation P-gp inhibitor as more potent and selective 2nd and 3rd generation molecules were subsequently developed for use as chemotherapy sensitizers. Several studies, including those by our group, have reported that Verapamil is capable of modulating inflammatory responses in human T-cells, animal models of asthma, and nasal polyps. Using an organotypic explant model, we have previously shown that Verapamil has similar effects to dexamethasone in its ability to abrogate Interleukin(IL)-5, IL-6, and Thymic Stromal Lymphopoietin secretion. While Verapamil is cardioactive, it is considered the first-line prophylactic drug for cluster headache and is usually well tolerated by otherwise healthy patients. In light of our prior studies demonstrating the immunomodulatory role of P-gp in promoting Th2 skewing cytokine secretion in CRSwNP, we hypothesized that low dose Verapamil HCl monotherapy would be safe and effective in the treatment of CRSwNP.
4 schema:endDate 2017-05-01T00:00:00Z
5 schema:keywords ATP hydrolysis
6 ATP-binding cassette
7 Adenosine Triphosphate
8 Bodily Secretion
9 CRSwNP
10 Cell Membrane
11 Cr
12 Europe
13 Formal Social Control
14 HCl
15 IL
16 Interleukin-6
17 Mucous Membrane
18 P-Glycoprotein
19 Recent evidence
20 Th2
21 United State
22 american
23 animal model
24 asthma
25 calcium channel blocker
26 cassette
27 chronic rhinosinusitis
28 corticosteroid
29 cytokine
30 cytokine secretion
31 dexamethasone
32 disease pathogenesis
33 double blind placebo
34 dysregulated immune response
35 efflux
36 eosinophilic inflammation
37 epithelial cell
38 evolving understanding
39 explants
40 first generation
41 first line
42 generation
43 headache
44 healthcare expenditure
45 healthy patient
46 helper T cell
47 human T cell
48 immunomodulatory role
49 inflammation
50 inflammatory pathway
51 inflammatory response
52 inhibitor
53 local immune response
54 low dose
55 mainstay
56 monotherapy
57 nasal polyp
58 novel therapy
59 overexpression
60 patient
61 polarizing
62 prevalence
63 primary driver
64 prior study
65 sensitizer
66 similar effect
67 substrate
68 target
69 tissue
70 transport
71 transporter
72 verapamil
73 wide range
74 schema:name Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis
75 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02454608
76 schema:sdDatePublished 2019-03-07T15:26
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher Ne823619ed80944838bcb66a109997e6e
79 schema:sponsor https://www.grid.ac/institutes/grid.39479.30
80 schema:startDate 2015-05-01T00:00:00Z
81 schema:subjectOf sg:pub.10.1007/s00011-005-0060-y
82 sg:pub.10.1007/s10194-010-0289-x
83 https://app.dimensions.ai/details/publication/pub.1078588337
84 https://doi.org/10.1002/alr.21072
85 https://doi.org/10.1016/0006-291x(89)91076-0
86 https://doi.org/10.1016/j.neuropharm.2012.05.033
87 https://doi.org/10.1016/j.pupt.2011.11.001
88 https://doi.org/10.1097/moo.0b013e32835bc3f9
89 https://doi.org/10.1111/head.12145
90 https://doi.org/10.1111/j.1749-4486.2009.01995.x
91 https://doi.org/10.1212/01.wnl.0000267319.18123.d3
92 https://doi.org/10.1253/circj.cj-09-0467
93 schema:url https://clinicaltrials.gov/show/NCT02454608
94 sgo:license sg:explorer/license/
95 sgo:sdDataset clinical_trials
96 rdf:type schema:MedicalStudy
97 Ne823619ed80944838bcb66a109997e6e schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 anzsrc-for:2581 schema:inDefinedTermSet anzsrc-for:
100 rdf:type schema:DefinedTerm
101 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
102 rdf:type schema:DefinedTerm
103 sg:pub.10.1007/s00011-005-0060-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1019965301
104 https://doi.org/10.1007/s00011-005-0060-y
105 rdf:type schema:CreativeWork
106 sg:pub.10.1007/s10194-010-0289-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1042829743
107 https://doi.org/10.1007/s10194-010-0289-x
108 rdf:type schema:CreativeWork
109 https://app.dimensions.ai/details/publication/pub.1078588337 schema:CreativeWork
110 https://doi.org/10.1002/alr.21072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003754472
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1016/0006-291x(89)91076-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041369857
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1016/j.neuropharm.2012.05.033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012770675
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1016/j.pupt.2011.11.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039786003
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1097/moo.0b013e32835bc3f9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009617454
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1111/head.12145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002529252
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1111/j.1749-4486.2009.01995.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046850455
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1212/01.wnl.0000267319.18123.d3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064349412
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1253/circj.cj-09-0467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008378333
127 rdf:type schema:CreativeWork
128 https://www.grid.ac/institutes/grid.39479.30 schema:Organization
 




Preview window. Press ESC to close (or click here)


...